Publicacións nas que colabora con Alfonso García de Coca (10)

2020

  1. Integrated genomic analysis of chromosomal alterations and mutations in B-cell acute lymphoblastic leukemia reveals distinct genetic profiles at relapse

    Diagnostics, Vol. 10, Núm. 7

2016

  1. Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia

    Leukemia Research, Vol. 40, pp. 1-9

2014

  1. Multiparameter flow cytometry for the identification of the Waldenström's clone in IgM-MGUS and Waldenström's Macroglobulinemia: New criteria for differential diagnosis and risk stratification

    Leukemia, Vol. 28, Núm. 1, pp. 166-173

  2. Mutation status and immunoglobulin gene rearrangements in patients from northwest and central region of Spain with chronic lymphocytic leukemia

    BioMed Research International, Vol. 2014

2012

  1. Molecular Characterization of Chronic Lymphocytic Leukemia Patients with a High Number of Losses in 13q14

    PLoS ONE, Vol. 7, Núm. 11

2011

  1. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma

    Leukemia, Vol. 25, Núm. 4, pp. 697-706

  2. The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis

    Blood, Vol. 117, Núm. 13, pp. 3613-3616

2010

  1. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: Comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells

    British Journal of Haematology, Vol. 148, Núm. 1, pp. 110-114

2009

  1. The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients

    Blood, Vol. 114, Núm. 20, pp. 4369-4372

2008

  1. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

    Blood, Vol. 112, Núm. 10, pp. 4017-4023